Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging.

Mo Y, Stromswold J, Wilson K, Holder D, Sur C, Laterza O, Savage MJ, Struyk A, Scheltens P, Teunissen CE, Burke J, Macaulay SL, Bråthen G, Sando SB, White LR, Weiss C, Cowes A, Bush MM, DeSilva G, Darby DG, Rainey-Smith SR, Surls J, Sagini E, Tanen M, Altman A, Luthman J, Egan MF.

Alzheimers Dement (Amst). 2017 Mar 6;6:201-209. doi: 10.1016/j.dadm.2017.02.004. eCollection 2017.

2.

Age at injury is associated with the long-term cognitive outcome of traumatic brain injuries.

Li W, Risacher SL, McAllister TW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative..

Alzheimers Dement (Amst). 2017 Mar 2;6:196-200. doi: 10.1016/j.dadm.2017.01.008. eCollection 2017.

3.

Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.

Alexopoulos P, Werle L, Roesler J, Thierjung N, Gleixner LS, Yakushev I, Laskaris N, Wagenpfeil S, Gourzis P, Kurz A, Perneczky R; Alzheimer’s Disease Neuroimaging Initiative (ADNI)..

Alzheimers Res Ther. 2016 Dec 9;8(1):51.

4.

Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology.

Schmitz TW, Nathan Spreng R; Alzheimer's Disease Neuroimaging Initiative..

Nat Commun. 2016 Nov 4;7:13249. doi: 10.1038/ncomms13249.

5.

Biomarkers for the Early Detection and Progression of Alzheimer's Disease.

Counts SE, Ikonomovic MD, Mercado N, Vega IE, Mufson EJ.

Neurotherapeutics. 2017 Jan;14(1):35-53. doi: 10.1007/s13311-016-0481-z. Review.

PMID:
27738903
6.

Type 2 diabetes mellitus is associated with brain atrophy and hypometabolism in the ADNI cohort.

Li W, Risacher SL, Huang E, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative..

Neurology. 2016 Aug 9;87(6):595-600. doi: 10.1212/WNL.0000000000002950. Epub 2016 Jul 6.

PMID:
27385744
7.

The C677T variant in MTHFR modulates associations between blood-based and cerebrospinal fluid biomarkers of neurodegeneration.

Roussotte FF, Narr KL, Small GW, Thompson PM; Alzheimer’s Disease Neuroimaging Initiative..

Neuroreport. 2016 Aug 17;27(12):948-51. doi: 10.1097/WNR.0000000000000636.

8.

Variants in CCL16 are associated with blood plasma and cerebrospinal fluid CCL16 protein levels.

Ebbert MT, Staley LA, Parker J, Parker S, Bailey M; Alzheimer’s Disease Neuroimaging Initiative., Ridge PG, Goate AM, Kauwe JS.

BMC Genomics. 2016 Jun 29;17 Suppl 3:437. doi: 10.1186/s12864-016-2788-x.

9.

Variants in ACPP are associated with cerebrospinal fluid Prostatic Acid Phosphatase levels.

Staley LA, Ebbert MT, Bunker D, Bailey M; Alzheimer’s Disease Neuroimaging Initiative., Ridge PG, Goate AM, Kauwe JS.

BMC Genomics. 2016 Jun 29;17 Suppl 3:439. doi: 10.1186/s12864-016-2787-y.

10.

Genome-wide association study of prolactin levels in blood plasma and cerebrospinal fluid.

Staley LA, Ebbert MT, Parker S, Bailey M; Alzheimer’s Disease Neuroimaging Initiative., Ridge PG, Goate AM, Kauwe JS.

BMC Genomics. 2016 Jun 29;17 Suppl 3:436. doi: 10.1186/s12864-016-2785-0.

11.

Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis.

Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Pérez JM, Evans AC; Alzheimer’s Disease Neuroimaging Initiative..

Nat Commun. 2016 Jun 21;7:11934. doi: 10.1038/ncomms11934.

12.

Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers.

DeMarshall CA, Nagele EP, Sarkar A, Acharya NK, Godsey G, Goldwaser EL, Kosciuk M, Thayasivam U, Han M, Belinka B, Nagele RG; Alzheimer's Disease Neuroimaging Initiative..

Alzheimers Dement (Amst). 2016 Apr 12;3:51-62. doi: 10.1016/j.dadm.2016.03.002. eCollection 2016.

13.

Molecular and cellular pathophysiology of preclinical Alzheimer's disease.

Mufson EJ, Ikonomovic MD, Counts SE, Perez SE, Malek-Ahmadi M, Scheff SW, Ginsberg SD.

Behav Brain Res. 2016 Sep 15;311:54-69. doi: 10.1016/j.bbr.2016.05.030. Epub 2016 May 13. Review.

PMID:
27185734
14.

Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults.

Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, Gao S, Boustani M, Crane PK, Petersen RC, Jack CR Jr, Jagust WJ, Aisen PS, Weiner MW, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative..

JAMA Neurol. 2016 Jun 1;73(6):721-32. doi: 10.1001/jamaneurol.2016.0580.

PMID:
27088965
15.

Traumatic brain injury and age at onset of cognitive impairment in older adults.

Li W, Risacher SL, McAllister TW, Saykin AJ.

J Neurol. 2016 Jul;263(7):1280-5. doi: 10.1007/s00415-016-8093-4. Epub 2016 Mar 23. Erratum in: J Neurol. 2016 Jul;263(7):1286.

PMID:
27007484
16.

Cross-View Neuroimage Pattern Analysis in Alzheimer's Disease Staging.

Liu S, Cai W, Pujol S, Kikinis R, Feng DD; Alzheimer's Disease Neuroimaging Initiative..

Front Aging Neurosci. 2016 Feb 23;8:23. doi: 10.3389/fnagi.2016.00023. eCollection 2016.

17.

CSF complement 3 and factor H are staging biomarkers in Alzheimer's disease.

Hu WT, Watts KD, Tailor P, Nguyen TP, Howell JC, Lee RC, Seyfried NT, Gearing M, Hales CM, Levey AI, Lah JJ, Lee EK; Alzheimer’s Disease Neuro-Imaging Initiative..

Acta Neuropathol Commun. 2016 Feb 17;4:14. doi: 10.1186/s40478-016-0277-8.

18.

Can Genetic Analysis of Putative Blood Alzheimer's Disease Biomarkers Lead to Identification of Susceptibility Loci?

Barber RC, Phillips NR, Tilson JL, Huebinger RM, Shewale SJ, Koenig JL, Mitchel JS, O'Bryant SE, Waring SC, Diaz-Arrastia R, Chasse S, Wilhelmsen KC; Alzheimer’s Disease Neuroimaging Initiative.; Texas Alzheimer’s Research and Care Consortium..

PLoS One. 2015 Dec 1;10(12):e0142360. doi: 10.1371/journal.pone.0142360. eCollection 2015.

19.

A Subset of Cerebrospinal Fluid Proteins from a Multi-Analyte Panel Associated with Brain Atrophy, Disease Classification and Prediction in Alzheimer's Disease.

Khan W, Aguilar C, Kiddle SJ, Doyle O, Thambisetty M, Muehlboeck S, Sattlecker M, Newhouse S, Lovestone S, Dobson R, Giampietro V, Westman E, Simmons A; Alzheimer’s Disease Neuroimaging Initiative..

PLoS One. 2015 Aug 18;10(8):e0134368. doi: 10.1371/journal.pone.0134368. eCollection 2015.

20.

The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.

Kang JH, Korecka M, Figurski MJ, Toledo JB, Blennow K, Zetterberg H, Waligorska T, Brylska M, Fields L, Shah N, Soares H, Dean RA, Vanderstichele H, Petersen RC, Aisen PS, Saykin AJ, Weiner MW, Trojanowski JQ, Shaw LM; Alzheimer's Disease Neuroimaging Initiative..

Alzheimers Dement. 2015 Jul;11(7):772-91. doi: 10.1016/j.jalz.2015.05.003. Review.

Supplemental Content

Support Center